SCHEMBL17828867

SCHEMBL17828867

c1ccc(-c2nc(-c3cccc(-n4c5ccccc5c5cc(-n6c7ccccc7c7ccccc76)ccc54)c3)nc3c2ccc2ccccc23)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.38
ATM Q13315 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP1B1 Q16678 1/20 0.34
WHR1 P49842 1/20 0.33
RAC2 P15153 1/20 0.33
RAC3 P60763 1/20 0.33
CDC42 P60953 1/20 0.33
RAC1 P63000 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
NPY5R Q15761 1/20 0.32
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32
PLA2G10 O15496 1/20 0.32
MAOA P21397 1/20 0.32
MAPT P10636 2/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17828869 0.98 ATM (0.36) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL17829045 0.97 L3MBTL1 (0.36) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL17828995 0.95 ATM (0.38) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL18213944 0.95 ATM (0.38) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL17828864 0.95 ATM (0.38) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL17829205 0.95 ATM (0.38) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL18026440 0.94 L3MBTL1 (0.39) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL17828806 0.94 L3MBTL1 (0.39) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL17828889 0.94 L3MBTL1 (0.39) L3MBTL1ATMKDM4ECYP1A1CYP1A2
SCHEMBL17828875 0.94 ATM (0.38) L3MBTL1ATMKDM4ECYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME L1CAM, LEF1, EML4 L3MBTL1 271/4885ATM 2921/4885KDM4E 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.